Dementia with Lewy Bodies (DLB) - Epidemiology Forecast - 2034

Report
88 Pages
April 2024
DelveInsight
ID: 5952950

Key Highlights

According to these estimates in 2022, the total diagnosed prevalent cases of dementia in the 7MM were nearly 11 million, with 0.6 million cases diagnosed as dementia with Lewy bodies (DLB). This figure is projected to rise by 2034 due to several factors such as aging populations, improved diagnostic criteria, increased awareness leading to earlier detection, and possibly other demographic or lifestyle-related factors.
According to the analysis, the United States reported the highest diagnosed prevalent cases of Dementia with Lewy Bodies (DLB), followed by Japan and the combined cases of EU4 and the UK countries in 2022. This trend suggests a significant burden of DLB across these regions, with anticipated future increases,
Our estimates suggest that among males and females, males have a higher number of diagnosed cases of Dementia with Lewy Bodies (DLB) across all age groups. Additionally, within all age groups, individuals aged 85 and above exhibit a higher prevalence of DLB, highlighting the significant impact of age on the prevalence of this condition.

The “Dementia with Lewy Bodies (DLB) - Epidemiology - 2034” report delivers an in-depth understanding of the Dementia with Lewy Bodies (DLB), historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan

Study Period: 2020-2034

Disease Understanding and Diagnostic Algorithm

Dementia with Lewy Bodies (DLB) Overview

Dementia with Lewy Bodies (DLB) is a progressive neurodegenerative disorder characterized by cognitive decline, visual hallucinations, fluctuations in attention and alertness, and motor symptoms similar to Parkinson's disease. It's the second most common type of degenerative dementia after Alzheimer's disease. Additionally, DLB is associated with REM sleep behavior disorder, wherein individuals act out vivid dreams during sleep, often preceding the onset of cognitive symptoms. These unique characteristics contribute to the complexity of diagnosing and managing DLB.

Dementia with Lewy Bodies (DLB) Diagnosis

DLB presents unique challenges in diagnosis and management due to its overlapping symptoms with other dementias and parkinsonian disorders, necessitating a comprehensive assessments integrating clinical, imaging, and biomarker data to enhance diagnostic accuracy and optimize patient care. Its diagnosis relies on clinical judgment and requires a high index of suspicion. Challenges arise from fluctuating cognitive symptoms, variable motor manifestations, and the prominence of visual hallucinations, often leading to misdiagnosis.

Dementia with Lewy Bodies (DLB) Epidemiology

For the purpose of designing the patient-based model for Dementia with Lewy Bodies (DLB), the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Dementia, Total Diagnosed Prevalent cases of Dementia, Total Diagnosed Prevalent cases of Dementia with Lewy Bodies, Gender-specific Diagnosed Prevalent Cases of DLB, and Age-specific Diagnosed Prevalent Cases of DLB in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

In 2022, the total prevalent cases of dementia in the 7MM were estimated at approximately 21 million, with around 11 million cases diagnosed. Projections indicate a rise in cases during the forecasted period from 2023 to 2034.
Among the 7MM countries, the United States stands out with the highest diagnosed prevalent cases of dementia, totaling around 5 million. Interestingly, only 5.9% of these cases are attributed to dementia with Lewy bodies.
Among EU4 and the UK, the diagnosed prevalent cases of DLB were highest in the UK with around 44 thousand cases, followed by Germany with over 38 thousand cases, while Spain accounted for the least cases with about 24 thousand in 2022.
In the 7MM, the analysis shows more DLB cases in males (around 0.3 million) than females (over 0.28 million) in 2022, with projected increases by 2034. This gender disparity in DLB diagnosed prevalence across the 7MM could stem from factors like genetic susceptibility and healthcare-seeking behavior, warranting further investigation.
In 2022, Japan ranked second after the US in diagnosed prevalent cases of DLB, comprising 22% of all cases in the 7MM. This underscores the significant burden of DLB in Japan and highlights the importance of addressing the challenges associated with this condition within the country's healthcare system.
Among the segmented age groups of 60-69 years, 70-74 years, 75-79 years, 80-84 years, and 85+ years, the highest number of cases was estimated to be in the group 85+ years, accounting for approximately 39% of the total diagnosed cases in the 7MM in 2022

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Dementia with Lewy Bodies (DLB) evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, along with challenges related to accessibility, including KOL from Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, US; National Institute on Ageing, US; German Center for Neurodegenerative Diseases (DZNE), Germany; Università degli studi g. d'annunzio chieti e pescara i, Italy; Department of Neurology and Neurobiology of Aging, Kanazawa, Japan, and others.

The analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Dementia with Lewy Bodies (DLB), explaining its causes, signs and symptoms, and pathogenesis.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and guidelines.
The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
A detailed review of current challenges in establishing the diagnosis.

Dementia with Lewy Bodies (DLB) Report Insights

Patient Population
Country-wise Epidemiology Distribution
Total Diagnosed Prevalence of Dementia with Lewy Bodies (DLB)
Total Diagnosed Prevalence of Dementia with Lewy Bodies (DLB)

Dementia with Lewy Bodies (DLB) Report Key Strengths

11 years Forecast
The 7MM Coverage
Dementia with Lewy Bodies (DLB) Epidemiology Segmentation

Key Questions

Epidemiology Insights

What are the disease risks, burdens, and unmet needs of C Dementia with Lewy Bodies (DLB)? What will be the growth opportunities across the 7MM concerning the patient population of Dementia with Lewy Bodies (DLB)?
What is the historical and forecasted Dementia with Lewy Bodies (DLB) patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
Why do only limited patients appear for diagnosis?
Which country is more diagnosed prevalent for Dementia with Lewy Bodies (DLB) and why?
What factors are affecting the diagnosis of the indication?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the Dementia with Lewy Bodies (DLB) prevalence cases in varying geographies over the coming years.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Dementia with Lewy Bodies (DLB) Epidemiology report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Dementia with Lewy Bodies (DLB) cases in 2023?
The highest cases of Dementia with Lewy Bodies (DLB) was found in the UK, among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Dementia with Lewy Bodies (DLB) cases in 2023?
The highest cases of Dementia with Lewy Bodies (DLB) were found in the US among the 7MM in 2023.

1. Key Insights2. Report Introduction

3. DLB Epidem Overview at a Glance

3.1. Patient Share (%) Distribution of DLB by Therapies in 2020
3.2. Patient Share (%) Distribution of DLB by Therapies in 2034

4. Epidemiology Forecast Methodology5. Executive Summary of DLB

6. DLB: Disease Background and Overview

6.1. Introduction
6.2. Classification of LBD
6.3. Etiology and Risk factors
6.4. Clinical Manifestations
6.5. Pathophysiology
6.5.1. Molecular mechanisms of Lewy body disorders
6.6. Diagnosis
6.6.1. Diagnostic Criteria for DLB
6.6.1.1. Diagnosis and management of DLB: Fourth consensus report of the DLB consortium
6.6.1.2. Diagnostic Criteria for Major Neurocognitive Disorder with Lewy Bodies (DSM-5)

7. Epidemiology and Patient Population of DLB

7.1. Key Findings
7.2. Assumptions and Rationale: The 7MM
7.2.1. The United States
7.2.2. EU4 and the United Kingdom
7.2.2.1. Germany
7.2.2.2. France
7.2.2.3. Italy
7.2.2.4. Spain
7.2.2.5. The UK
7.2.3. Japan
7.3. Total Prevalent cases of Dementia in the 7MM
7.4. Total Diagnosed Prevalent cases of Dementia in the 7MM
7.5. Total Diagnosed Prevalent cases of DLB in the 7MM
7.6. The United States
7.6.1. Prevalent cases of Dementia in the US
7.6.2. Diagnosed Prevalent cases of Dementia in the US
7.6.3. Diagnosed Prevalent cases of DLB in the US
7.6.4. Gender-specific Diagnosed Prevalent cases of DLB in the US
7.6.5. Age-specific Diagnosed Prevalent cases of DLB in the US
7.7. EU4 and the UK
7.7.1. Germany
7.7.1.1. Prevalent cases of Dementia in Germany
7.7.1.2. Diagnosed Prevalent cases of Dementia in Germany
7.7.1.3. Diagnosed Prevalent cases of DLB in Germany
7.7.1.4. Gender-specific Diagnosed Prevalent cases of DLB in Germany
7.7.1.5. Age-specific Diagnosed Prevalent cases of DLB in Germany
7.7.2. France
7.7.2.1. Prevalent cases of Dementia in France
7.7.2.2. Diagnosed Prevalent cases of Dementia in France
7.7.2.3. Diagnosed Prevalent cases of DLB in France
7.7.2.4. Gender-specific Diagnosed Prevalent cases of DLB in France
7.7.2.5. Age-specific Diagnosed Prevalent cases of DLB in France
7.7.3. Italy
7.7.3.1. Prevalent cases of Dementia in Italy
7.7.3.2. Diagnosed Prevalent cases of Dementia in Italy
7.7.3.3. Diagnosed Prevalent cases of DLB in Italy
7.7.3.4. Gender-specific Diagnosed Prevalent cases of DLB in Italy
7.7.3.5. Age-specific Diagnosed Prevalent cases of DLB in Italy
7.7.4. Spain
7.7.4.1. Prevalent cases of Dementia in Spain
7.7.4.2. Diagnosed Prevalent cases of Dementia in Spain
7.7.4.3. Diagnosed Prevalent cases of DLB in Spain
7.7.4.4. Gender-specific Diagnosed Prevalent cases of DLB in Spain
7.7.4.5. Age-specific Diagnosed Prevalent cases of DLB in Spain
7.7.5. The UK
7.7.5.1. Prevalent cases of Dementia in the UK
7.7.5.2. Diagnosed Prevalent cases of Dementia in the UK
7.7.5.3. Diagnosed Prevalent cases of DLB in the UK
7.7.5.4. Gender-specific Diagnosed Prevalent cases of DLB in the UK
7.7.5.5. Age-specific Diagnosed Prevalent cases of DLB in the UK
7.8. Japan
7.8.1. Prevalent cases of Dementia in Japan
7.8.2. Diagnosed prevalent cases of Dementia in Japan
7.8.3. Diagnosed prevalent cases of DLB in Japan
7.8.4. Gender-specific Diagnosed Prevalent cases of DLB in Japan
7.8.5. Age-specific Diagnosed Prevalent cases of DLB in Japan

8. Patient Journey9. Key Opinion Leaders’ View

10. Appendix

10.1. Bibliography
10.2. Acronyms and Abbreviations
10.3. Report Methodology

11. Publisher Capabilities12. Disclaimer13. About the Publisher

List of Tables

Table 1: Summary of DLB Epidemiology (2020-2034)
Table 2: Classification of LBD
Table 3: Revised Criteria for the Clinical Diagnosis of Probable and Possible DLB (2017) According to the Fourth report of the DLB Consortium
Table 4: Total Prevalent cases of Dementia in the 7MM, in ‘000’ (2020-2034)
Table 5: Diagnosed Prevalent cases of Dementia in the 7MM, in ‘000’ (2020-2034)
Table 6: Total Diagnosed Prevalent cases of DLB in the 7MM, in ‘000’ (2020-2034)
Table 7: Prevalent cases of Dementia in the US, in ‘000’ (2020-2034)
Table 8: Diagnosed Prevalent cases of Dementia in the US, in ‘000’ (2020-2034)
Table 9: Diagnosed Prevalent cases of DLB in the US, in ‘000’ (2020-2034)
Table 10: Gender-specific Diagnosed Prevalent cases of DLB in the US, in ‘000’ (2020-2034)
Table 11: Age-specific Diagnosed Prevalent cases of DLB in the US, in ‘000’ (2020-2034)
Table 12: Total Prevalent cases of Dementia in EU4 and the UK, in ‘000’ (2020-2034)
Table 13: Diagnosed Prevalent cases of Dementia in EU4 and the UK, in ‘000’ (2020-2034)
Table 14: Diagnosed Prevalent cases of DLB in EU4 and the UK, in ‘000’ (2020-2034)
Table 15: Gender-specific Diagnosed Prevalent cases of DLB in EU4 and the UK, in ‘000’ (2020-2034)
Table 16: Age-specific Diagnosed Prevalent cases of DLB in EU4 and the UK, in ‘000’ (2020-2034)
Table 17: Total Prevalent cases of Dementia in Germany, in ‘000’ (2020-2034)
Table 18: Diagnosed Prevalent cases of Dementia in Germany, in ‘000’ (2020-2034)
Table 19: Diagnosed Prevalent cases of DLB in Germany, in ‘000’ (2020-2034)
Table 20: Gender-specific Diagnosed Prevalent cases of DLB in Germany, in ‘000’ (2020-2034)
Table 21: Age-specific Diagnosed Prevalent cases of DLB in Germany, in ‘000’ (2020-2034)
Table 22: Total Prevalent cases of Dementia in France, in ‘000’ (2020-2034)
Table 23: Diagnosed Prevalent cases of Dementia in France, in ‘000’ (2020-2034)
Table 24: Diagnosed Prevalent cases of DLB in France, in ‘000’ (2020-2034)
Table 25: Gender-specific Diagnosed Prevalent cases of DLB in France, in ‘000’ (2020-2034)
Table 26: Age-specific Diagnosed Prevalent cases of DLB in France, in ‘000’ (2020-2034)
Table 27: Age-specific Diagnosed Prevalent cases of DLB in Italy, in ‘000’ (2020-2034)
Table 28: Total Prevalent cases of Dementia in Italy, in ‘000’ (2020-2034)
Table 29: Diagnosed Prevalent cases of Dementia in Italy, in ‘000’ (2020-2034)
Table 30: Diagnosed Prevalent cases of DLB in Italy, in ‘000’ (2020-2034)
Table 31: Gender-specific Diagnosed Prevalent cases of DLB in Italy, in ‘000’ (2020-2034)
Table 32: Age-specific Diagnosed Prevalent cases of DLB in Italy, in ‘000’ (2020-2034)
Table 33: Total Prevalent cases of Dementia in Spain, in ‘000’ (2020-2034)
Table 34: Diagnosed Prevalent cases of Dementia in Spain, in ‘000’ (2020-2034)
Table 35: Diagnosed Prevalent cases of DLB in Spain, in ‘000’ (2020-2034)
Table 36: Gender-specific Diagnosed Prevalent cases of DLB in Spain, in ‘000’ (2020-2034)
Table 37: Age-specific Diagnosed Prevalent cases of DLB in Spain, in ‘000’ (2020-2034)
Table 38: Total Prevalent cases of Dementia in the UK, in ‘000’ (2020-2034)
Table 39: Diagnosed Prevalent cases of Dementia in the UK, in ‘000’ (2020-2034)
Table 40: Diagnosed Prevalent cases of DLB in the UK, in ‘000’ (2020-2034)
Table 41: Gender-specific Diagnosed Prevalent cases of DLB in the UK, in ‘000’ (2020-2034)
Table 42: Age-specific Diagnosed Prevalent cases of DLB in the UK, in ‘000’ (2020-2034)
Table 43: Total Prevalent cases of Dementia in Japan, in ‘000’ (2020-2034)
Table 44: Diagnosed Prevalent cases of Dementia in Japan, in ‘000’ (2020-2034)
Table 45: Diagnosed Prevalent cases of DLB in Japan, in ‘000’ (2020-2034)
Table 46: Gender-specific Diagnosed Prevalent cases of DLB in Japan, in ‘000’ (2020-2034)
Table 47: Age-specific Diagnosed Prevalent cases of DLB in Japan, in ‘000’ (2020-2034)

List of Figures

Figure 1: Risk Factors of LBD
Figure 2: Symptoms of DLB
Figure 3: Pathogenesis of LBD
Figure 4: Principal Neural Pathways and Brain Areas affected in the Parkinsonism Dementia Complex
Figure 5: Molecular Mechanisms of LBD
Figure 6: Diagnosis Algorithm of DLB
Figure 7: Total Prevalent cases of Dementia in the 7MM, in ‘000’ (2020-2034)
Figure 8: Diagnosed Prevalent cases of Dementia in the 7MM, in ‘000’ (2020-2034)
Figure 9: Total Diagnosed Prevalent cases of DLB in the 7MM, in ‘000’ (2020-2034)
Figure 10: Prevalent cases of Dementia in the US, in ‘000’ (2020-2034)
Figure 11: Diagnosed Prevalent cases of Dementia in the US, in ‘000’ (2020-2034)
Figure 12: Diagnosed Prevalent cases of DLB in the US, in ‘000’ (2020-2034)
Figure 13: Gender-specific Diagnosed Prevalent cases of DLB in the US, in ‘000’ (2020-2034)
Figure 14: Age-specific Diagnosed Prevalent cases of DLB in the US, in ‘000’ (2020-2034)
Figure 15: Total Prevalent cases of Dementia in EU4 and the UK, in ‘000’ (2020-2034)
Figure 16: Diagnosed Prevalent cases of Dementia in EU4 and the UK, in ‘000’ (2020-2034)
Figure 17: Diagnosed Prevalent cases of DLB in EU4 and the UK, in ‘000’ (2020-2034)
Figure 18: Gender-specific Diagnosed Prevalent cases of DLB in EU4 and the UK, in ‘000’ (2020-2034)
Figure 19: Age-specific Diagnosed Prevalent cases of DLB in EU4 and the UK, in ‘000’ (2020-2034)
Figure 20: Total Prevalent cases of Dementia in Germany, in ‘000’ (2020-2034)
Figure 21: Diagnosed Prevalent cases of Dementia in Germany, in ‘000’ (2020-2034)
Figure 22: Diagnosed Prevalent cases of DLB in Germany, in ‘000’ (2020-2034)
Figure 23: Gender-specific Diagnosed Prevalent cases of DLB in Germany, in ‘000’ (2020-2034)
Figure 24: Age-specific Diagnosed Prevalent cases of DLB in Germany, in ‘000’ (2020-2034)
Figure 25: Total Prevalent cases of Dementia in France, in ‘000’ (2020-2034)
Figure 26: Diagnosed Prevalent cases of Dementia in France, in ‘000’ (2020-2034)
Figure 27: Diagnosed Prevalent cases of DLB in France, in ‘000’ (2020-2034)
Figure 28: Gender-specific Diagnosed Prevalent cases of DLB in France, in ‘000’ (2020-2034)
Figure 29: Age-specific Diagnosed Prevalent cases of DLB in France, in ‘000’ (2020-2034)
Figure 30: Age-specific Diagnosed Prevalent cases of DLB in Italy, in ‘000’ (2020-2034)
Figure 31: Total Prevalent cases of Dementia in Italy, in ‘000’ (2020-2034)
Figure 32: Diagnosed Prevalent cases of Dementia in Italy, in ‘000’ (2020-2034)
Figure 33: Diagnosed Prevalent cases of DLB in Italy, in ‘000’ (2020-2034)
Figure 34: Gender-specific Diagnosed Prevalent cases of DLB in Italy, in ‘000’ (2020-2034)
Figure 35: Age-specific Diagnosed Prevalent cases of DLB in Italy, in ‘000’ (2020-2034)
Figure 36: Total Prevalent cases of Dementia in Spain, in ‘000’ (2020-2034)
Figure 37: Diagnosed Prevalent cases of Dementia in Spain, in ‘000’ (2020-2034)
Figure 38: Diagnosed Prevalent cases of DLB in Spain, in ‘000’ (2020-2034)
Figure 39: Gender-specific Diagnosed Prevalent cases of DLB in Spain, in ‘000’ (2020-2034)
Figure 40: Age-specific Diagnosed Prevalent cases of DLB in Spain, in ‘000’ (2020-2034)
Figure 41: Total Prevalent cases of Dementia in the UK, in ‘000’ (2020-2034)
Figure 42: Diagnosed Prevalent cases of Dementia in the UK, in ‘000’ (2020-2034)
Figure 43: Diagnosed Prevalent cases of DLB in the UK, in ‘000’ (2020-2034)
Figure 44: Gender-specific Diagnosed Prevalent cases of DLB in the UK, in ‘000’ (2020-2034)
Figure 45: Age-specific Diagnosed Prevalent cases of DLB in the UK, in ‘000’ (2020-2034)
Figure 46: Total Prevalent cases of Dementia in Japan, in ‘000’ (2020-2034)
Figure 47: Diagnosed Prevalent cases of Dementia in Japan, in ‘000’ (2020-2034)
Figure 48: Diagnosed Prevalent cases of DLB in Japan, in ‘000’ (2020-2034)
Figure 49: Gender-specific Diagnosed Prevalent cases of DLB in Japan, in ‘000’ (2020-2034)
Figure 50: Age-specific Diagnosed Prevalent cases of DLB in Japan, in ‘000’ (2020-2034)
Figure 51: Patient Journey

PURCHASE OPTIONS

Single User License PDF

Site License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€3753EUR$3,950USD£3,218GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7505EUR$7,900USD£6,436GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€11258EUR$11,850USD£9,653GBP